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ABSTRACT
Myelodysplastic syndromes (MDS) represent a broad spectrum of diseases 
characterized by their clinical manifestation as one or more cytopenias, or a reduction 
in circulating blood cells. MDS is predominantly a disease of the elderly, with a 
median age in the UK of around 75. Approximately one third of MDS patients will 
develop secondary acute myeloid leukemia (sAML) that has a very poor prognosis. 
Unfortunately, most standard cytotoxic agents are often too toxic for older patients. 
This means there is a pressing unmet need for novel therapies that have fewer side 
effects to assist this vulnerable group. This challenge was tackled using bioinformatic 
analysis of available transcriptomic data to establish a gene-based signature of 
the development and progression of MDS. This signature was then used to identify 
novel therapeutic compounds via statistically-significant connectivity mapping. 
This approach suggested re-purposing an existing and widely-prescribed drug, 
bromocriptine as a novel potential therapy in these disease settings. This drug has 
shown selectivity for leukemic cells as well as synergy with current therapies.
INTRODUCTION
Myelodysplastic syndromes (MDS) are a set of 
diseases related by their clinical features and underlying 
etiology and considered a disease of the elderly, with a 
median age of around 75 [1]. Despite the initial cytopenias 
caused by dysplastic or failing bone marrow, roughly one 
third of MDS patients will develop a neoplastic secondary 
acute myeloid leukemia (sAML) that has a very poor 
prognosis. Those with high-risk MDS, defined by more 
severe clinical symptoms and certain cytogenetic features, 
are most in danger of progression [2]. Unfortunately, most 
gold-standard chemotherapies elicit excessive toxicity in 
this relatively frail, older patient group. This has driven 
research into trying to identify novel therapies, which 
have fewer side effects, to assist this vulnerable group. 
Low dose Cytarabine has already been trailed in the 
elderly population in treating more aggressive myeloid 
malignancies and successfully reduced disease burden 
[3, 4]. However, remission and relapse rates are still 
poor. Traditional drug discovery approaches have been 
financially and temporally burdensome; relying on either 
clinical trials in humans or large tissue culture-based drug 
screening schemes. In recent years, the pharmaceutical 
world has come to recognize that these methodologies are 
very inefficient in realizing successful new therapies. This 
has led to an increase in drug re-purposing strategies that 
seek to improve the chances of success, by eliminating 
the pitfalls of first-in-man trials and unpredicted 
toxicity [5, 6]. One such approach is connectivity mapping 
(cMAP). First developed by Lamb, et al., it is based on 
the empirical observation that a transcriptome reflects the 
state of a cell in a given condition [7, 8]. On this basis, it 
theorizes that a pattern of transcriptional change induced 
in one state may be reversed by the opposite pattern of 
change observed in another state. By example, a cancer 
cell with a characteristic change in transcription from 
normal may be phenotypically ‘normalized’ by a drug 
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which triggers an opposite change in the expression of 
those genes. The two major benefits of this approach are 
that the initial screen is done in silico and that it can allow 
for re-purposing of existing pharmaceutical agents, as 
the transcriptional response to many existing agents has 
already been profiled and made publically available.
This research has applied a statistically significant 
variant of cMAP, sscMap, [9] to the task of identifying new 
therapies for MDS and AML (Figure 1A). This approach 
has revealed a novel potential therapy in re-purposing an 
existing and widely-prescribed drug, bromocriptine. The 
drug has shown selectivity for the leukaemic cell as well 
as synergy with current therapies.
RESULTS 
Identification of gene signature of MDS 
development and progression
The gene expression dataset employed in this study 
was derived from two published datasets listed on the 
GEO repository as GSE13159 [10] and GSE15061 [11]. 
The derived sample set included healthy donors (70) and 
patients with MDS (229) or AML (224, including all 
risk groups). However, all those AML patients that had 
cytogenetic rearrangements that typically preclude prior 
undetected MDS were excluded from analysis, such as 
Figure 1: (A) Overview of analytical approach (B) Kaplan-Meier for probability of AML transformation (C) Heatmap of expression 
for 50–50 gene signature (D) sscMap drug-signature connections. (A) Flowchart of analysis pipeline used to generate gene signature 
and identify compounds using sscMap (B) A Kaplan-Meier plot illustrating the stratification of a subset of MDS patient gene expression 
profiles between the prognostic classes and their risk of leukemic transformation (low, medium & high risk of transformation) (C) 
Hierarchical cluster of patient and donor gene expression profiles based on the identified 50–50 gene signature. Colored bars indicate 
patient or donor status. The model cell lines included in the screen are also represented in the heatmap and are connected to the heatmap 
to highlight their positioning. The expression values are presented as absolute microarray intensity values with yellow representing 
high expression and blue low expression. The grey and black bars underneath delineate the four clusters in the dendrogram, which are 
further discussed in the text. (D) A volcano plot of the connection scores and p-values generated by the sscMap tool between the gene 
expression signature and the broad institute perturbagen library. Each point represents a derived gene signature to perturbagen/cell line 
connection. The red line represents the threshold of statistical significance (~3.573, p-value = ~2.675 × 10–4) for the sscMap algorithm. 
There were 8 significant connections across all the signatures, all of which had a negative score and represented 4 drugs. The drugs with ≥ 2 
connections are in bold.
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t (8;21) or inv (16). Mills, et al. previously developed a 
prognostic classifier (PC) that would stratify MDS patients 
by time to AML transformation based on their gene 
expression profiles [11].The MDS sample profiles were 
classified using the PC as either, low (n = 146), medium 
(n = 44) or high risk (n = 39) of transformation (PC-Risk). 
Out of the 229 MDS gene expression profiles our group 
had access to linked survival and progression to AML 
times for 115. This subset of samples showed a similar 
Kaplan-Meier pattern between the risk group assigned by 
the PC and time to AML transformation (Figure 1B) to 
that shown in the original publication [11]. 
The gene expression profiles were imported as raw 
CEL files and normalized using the appropriate Brainarray 
Chip Definition File (CDF) providing a more concise 
and accurate group of probe sets based on up-to-date 
genome information [12]. Statistical analysis by ANOVA 
of the microarray data across the groups (normal, low, 
medium, high PC-Risk & AML) yielded a large list of 
differentially expressed genes (DEGs) meeting an FDR-
adjusted p-value threshold of 0.05. Of these DEGs, 1, 303 
showed a positive (700) or negative (603) fold-change for 
every pairwise comparison, i.e. consistently increasing 
or decreasing, comprising a signature of development 
and progression. However, only 928 DEGs have a probe 
set on all the U133A platforms used for connectivity 
mapping. Coincidentally, there were 464 increasing and 
464 decreasing genes that could be used to interrogate the 
sscMap database. The top 50, ranked by p-value, of each 
of these lists (increasing and decreasing genes) formed 
the basis of a progression gene signature (50–50 gene list) 
(Supplementary Table 1).
In order to visualize the effectiveness of the 50–50 
gene list in categorizing patients we then performed 
complete linkage clustering of both the samples and 
the changes in individual gene expression creating the 
heatmap seen in Figure 1C. Four clusters were identifiable; 
the leftmost black cluster (1) holds the majority of the 
AML samples and only a few high-risk MDS samples 
together with the model cell lines, representing a high-
risk MDS (MDS-L) and AML (OCI/AML-3) in duplicate. 
The next cluster (2) is also predominated by AML samples 
and high-risk MDS samples. However, there are a few 
low-risk MDS and healthy samples. The third cluster 
(3) is predominated by healthy and low-risk MDS 
samples, including only a single AML sample. The final 
grey cluster (4) is more heterogeneous, but is also mostly 
healthy and low-risk MDS samples. Interestingly, the 
medium-risk MDS samples are distributed throughout all 
clusters, highlighting the heterogeneity of this group.
Discovery of drug connections via sscMap
The top 50, 40, 30, 20 or 10 genes from the 
increasing and decreasing gene lists were combined to 
form 5 derivative gene signatures of 100, 80, 60, 40 and 
20 genes; these 5 signatures were connected by sscMap 
to the Broad Institute cmap02 perturbagen database. 
Those compounds with a negative connection score 
(potential ‘inhibitors’ of development/progression) that 
were identified as significant by at least two signatures 
were considered of interest. Of the four drugs identified 
only 3 compounds (in bold) met the stricter criteria 
(Figure 1D). Importantly, all the significant connections 
in every comparison were for the leukemic cell line HL-60 
in the cmap02 database. The compounds were buspirone, 
bromocriptine, and tretinoin (ATRA). Tretinoin (ATRA) 
has already proven successful in a number of clinical trials 
for MDS and AML [13, 14]. Its molecular action triggers 
greater cell differentiation and appears to lead to an 
increase in terminally-differentiated hematopoietic cells in 
patients when used in combination with other agents, such 
as EPO or epigenetic modifiers [15, 16]. The other two 
compounds belonging to the neuroleptic class of drugs, 
however, have never, to the knowledge of the authors, 
been trailed in the context of treating hematological 
malignancies.
Screening of novel compounds
In light of the wealth of data surrounding 
tretinoin, only buspirone and bromocriptine were taken 
forward for initial screening in the MDS-L and OCI/
AML-3 cells, representing high-risk MDS and AML, 
respectively. Bromocriptine, a dopamine agonist, was 
shown to be considerably toxic against both cell lines, 
and significantly more so than buspirone (Figure 2A). 
In order to assess whether bromocriptine’s toxicity was 
common to other dopamine modulating agents, a panel of 
similar compounds were screened against the model cell 
lines, including some other neuroleptic class compounds 
(Figure 2B and 2C).
The expression of this neuroleptic class of receptors 
in the model cell lines was investigated in RMA-
normalized microarray data. Only three (DRD2, DRD4, 
HTR3C) of the twenty possible dopamine / serotonin 
receptors demonstrated above background expression ( > 4 
log2 intensity value – red line) in all the cell line samples 
studied (Supplementary Figure 1A) — with even these 
exhibiting very modest (< 5.5 log2 intensity value – blue 
line) compared to overall probe set intensity distribution 
(Supplementary Figure 1B). This would suggest that 
it is unlikely that the cells are sensitive to signaling via 
the dopamine / serotonin receptors. The dopamine and 
serotonin family of receptors have many members and 
each compound tested showed different affinities for 
each. The panel included dopamine agonists against all 
5 dopamine subtypes and those serotonin receptors for 
which bromocriptine has been shown to have affinity 
(Ki < 100 nM) [17] (Bold genes in Supplementary 
Figure 1A).
However, only one of the compounds tested 
elicited a viability response of similar magnitude as 
seen with bromocriptine: Dihydrexidine which is a 
Oncotarget6612www.impactjournals.com/oncotarget
dopamine 1 agonist, an activity which bromocriptine also 
possesses to some degree. However, it has an unfavorable 
pharmacokinetic profile, which limited its clinical utility, 
as it led to profound hypotension in the clinic [18]. 
Furthermore, it seems to have a very limited therapeutic 
window as its response profile has a much steeper curve. 
Two further model cell lines, SKM-1 and OCI/AML-2, 
were treated with bromocriptine eliciting a similar 
reduction in viability (Figure 2D).
Bromocriptine induces apoptosis and decreases 
colony formation
Cleavage of Poly ADP Ribose Phoshorylase 
(PARP), a commonly-employed marker of the final 
stages of apoptosis, was used to identify the mode of cell 
death elicited by bromocriptine. While PARP cleavage at 
48 h was marginal, by 72 h it was substantial, following 
treatment with bromocriptine (Figure 3A) with doses close 
to the 72 h IC50 as estimated during the initial screen. 
Caspase 3 is upstream of PARP in the apoptotic cascade 
and is one of the enzymes that catalyze its cleavage. 
This protein is itself cleaved relatively early in apoptosis 
signaling; as seen in Figure 3A; there is demonstrable 
Caspase 3 cleavage by 24 h prior to any detectable PARP 
cleavage. Caspase 3 cleavage was also seen using a 
substrate-based assay (Figure 3B) and was seen equally in 
both the MDS-L and OCI/AML-3 cell lines. 
To better predict in vivo effectiveness and 
investigate whether bromocriptine may have any effects 
on colony forming ability, methylcellulose assays were 
performed. MDS-L cells were pre-treated for 18 h with 
bromocriptine at various doses (0, 1, 10 µM) and seeded 
into cytokine supplemented methylcellulose. Equal cell 
numbers were used at the time of plating to correct for any 
cell death in the first 18h to specifically select for defects 
colony in formation. There was a very significant decrease 
in colony formation following bromocriptine treatment at 
10 µM (Figure 3C).
Synergy with standard agents and selectivity for 
the leukemic cell
The identification of bromocriptine via sscMap 
implied that it interferes with the specific transcriptional 
programs involved in MDS development and 
progression however its actual selectivity is not assured. 
To address this issue, mobilized peripheral blood 
mononuclear cells from two healthy donors, who had 
been conditioned using G-CSF together with three 
primary diagnostic AML samples were collected and 
their individual sensitivity to bromocriptine assessed. 
The results demonstrate a therapeutic window between 
the leukaemic and the healthy cells (Figure 4A). This 
infers that the action of bromocriptine is selective for 
the leukemic cell.
Figure 2: Drug dose-response in cell lines. Cell viability measured via ATP-based high-throughput assay normalized to vehicle-
treated control. Drug doses are represented as logarithm base 10 of Molarity. Points represent averages from 3 replicates and error bars 
represent SEM. (A) Bromocriptine & Buspirone screened against MDS-L and OCI/AML-3 (B) Neuroleptic compound screen against 
MDS-L (C) Neuroleptic compound screen against OCI/AML-3 (D) Bromocriptine-treated SKM-1 & OCI/AML-2 cell lines.
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In order to assess the interaction of bromocriptine 
with routine leukemia therapeutics, synergy was 
evaluated by treating cells with combinations of 
bromocriptine and cytarabine. The cells were treated in 
liquid culture at 0, 0.25, 0.5, 1 and 2 × the 72H IC50 doses 
of each drug combinatorially, i.e. 25 (5 × 5) individual 
treatments (Figure 4B and Supplementary Figure 2). 
The Combination Index values were calculated using the 
CalcuSyn software according to the method previously 
reported by Chou-Talalay et al [19]. The OCI/AML-3 cell 
line exhibited synergism (CI < 1) at all doses tested. The 
MDS-L cell line showed synergism at the higher doses, 
with lower doses eliciting an additive effect (CI ≈ 1) and 
still lower doses implying mild antagonism (CI > 1). 
However, this low-dose antagonism is likely a limitation 
of the algorithm itself and is a common finding for anti-
cancer drugs [20, 21].
DISCUSSION
Several studies have reported alterations in 
the transcriptional program of cells in MDS patients 
both in relation to healthy cells and across severity of 
disease [22, 23]. This study has sought to harness these 
changes during the development and progression of the 
disease to identify potential novel therapeutic agents. 
This approach has uncovered a gene signature which 
showed a consistent increasing or decreasing trend in 
expression across the disease spectrum from normal 
bone marrow, MDS patients with low, intermediate and 
high risk of transformation and de novo AML. Clustering 
of the patient transcriptomes by these genes led to a 
number of distinct clusters, chiefly around the expected 
groups, reinforcing the suitability of the gene signature. 
Interestingly, the medium-risk MDS samples are 
Figure 3: (A) Caspase/PARP cleavage (B) Caspase activity assay. (C) Methylcellulose colony assay. (A) Western blots of cell lysates 
probed for Caspase 3 (C3) and poly ADP ribose polymerase (PARP) and their cleaved forms at the labelled time points post bromocriptine 
treatment of OCI/AML-3 cells. Images are representative of westerns replicated three times. Arrowheads indicate cleaved PARP (B) Caspase 
3/7 activity 24 h after bromocriptine treatment; measured via luminescent DEVD peptide-cleavage assay. Values represent averages from 
duplicates and error bars represent standard error of the mean. (C) Methylcellulose-based colony-forming assay for MDS-L cell line with 
representative image.
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distributed throughout all clusters. This perhaps reflects 
the clinical heterogeneity in those MDS patients that are 
neither indolent nor AML-like.
Perhaps not surprisingly, the gene signature itself 
contains many genes with established roles in MDS and 
AML. For example, 7 members of the HOX genes, a 
gene family known to be important in both normal and 
malignant hematopoiesis, are included [24]. Moreover, 
WT1, CDK6 and FLT3, well-established drivers of 
leukemogenesis, [25–27] also form part of the increasing 
component. The presence of these genes in the signature 
may indicate value in its investigation as a mechanism of 
monitoring disease progression. However, the principal 
goal of this research was to leverage this signature to 
identify new and re-purposed therapies for MDS using 
sscMap, without the need to screen a multitude of 
individual targets. The other benefit of the connectivity 
mapping approach is that re-purposed drugs are three 
times more likely to be approved than novel agents [5, 6]. 
The potential of connectivity mapping has been 
shown many times before [28–32], but we believe that 
this is its first reported use in identifying drugs to re-
purpose for the treatment of MDS and AML. The use of 
the improved statistically-significant approach together 
with multiple gene signatures [29] and the updated, and 
more robust, chip definition file (CDF) microarray probe-
mapping [12] had increased the chances of a successful 
hit. Indeed, the identification of ATRA by the sscMap 
algorithm added significant authority to and validation 
of the process. sscMap identified two other compounds 
with potential anti-leukemic effects, with bromocriptine 
proving itself worthy of further in vivo and clinical 
investigation given our positive pre-clinical results.
In terms of drug re-purposing, a compound which 
shows an additive or synergistic effect with established 
therapies is more likely to be accepted by both physicians 
and patients themselves. The current gold-standard in the 
treatment of high-risk MDS and AML is cytarabine. Of 
particular relevance is the apparent success of low doses 
of this compound in treating elderly MDS/AML patients 
unable to undergo more aggressive regimens [33–35]. In 
these cases any compound that enhances effectiveness 
without significant side-effect would be of huge benefit 
to these patients. 
Bromocriptine shows synergy with cytarabine in 
the more proliferative OCI/AML-3 cell line at all doses 
tested. Its effect on the MDS-L cell line is less dramatic, 
but many doses do show synergy and the rest are mostly 
additive in their effect. This suggests that bromocriptine 
is more active in combination with cytarabine on more 
proliferative cells; selectivity that most chemotherapies 
aim for.
Bromocriptine as a therapeutic agent is non-toxic 
and has been widely-prescribed for decades with minimal 
side-effects. It is traditionally prescribed to treat pituitary-
related syndromes, such as hyperprolactinemia, but 
it has also more recently found use in the management 
of Parkinson’s symptoms. While at the highest dose 
Figure 4: (A) Primary mononuclear cell response to bromocriptine (B) Synergy of Bromocriptine and cytarabine. 
(A) Dose-response curve using ATP-based viability assay normalized to vehicle-treated cells. Samples represent peripheral blood 
mononuclear cells (PBMCs) from diagnostic AML samples or mobilized bone marrow donors. Points represent averages from 3 replicates 
and error bars represent SEM. (B) CalcuSyn synergy plots illustrating Combination Indices for doses of cytarabine and bromocriptine at 
and around the individual drug 72 h IC50 values. Values at 1.0 represent additive effect, whereas values below 1.0 suggest synergistic effect.
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used in this study it could be associated with increased 
side-effects in patients, these should be manageable in 
a combination setting, especially when compared to 
highly-toxic chemotherapy-only regimens. We have now 
shown it to possess efficacy against both leukemic and 
myelodysplastic cell lines. The exact mode-of-action of 
bromocriptine in achieving this remains unknown. Given 
the ineffectiveness of a host of other pharmacologically 
similar compounds in the same assay; its activity appears 
to be unrelated to its main action as a dopamine agonist. 
For the same reason, neither does it appear to concern its 
weaker engagement of other targets, such as serotonin 
receptors or excitatory amino acid transporters. These 
findings tally well with the lack of significant expression 
of this class of receptors on the model cell lines, in 
contrast to many solid tumours, [36] some of which 
show a proliferative response [37]. Furthermore, the 
compounds tested included Cabergoline, which is now 
superseding bromocriptine in the clinic [38], both of which 
are hypothesized to inhibit prolactin production [39]. 
The ineffectiveness of Cabergoline in our screens 
suggests it is unlikely that the prolactin inhibitory 
effect of bromocriptine explains it value. This suggests 
that bromocriptine has an as yet unknown molecular 
effect that triggers apoptosis in leukaemic cells. 
This is not the only case of a dopamine modulator 
demonstrating an anti-cancer effect, suggesting that 
this class of compounds is worth further investigation 
[40]. Indeed, there is a case study dating from 
1981 of a diabetic patient on chronic bromocriptine 
therapy demonstrating marked leukopenia [41]. 
Interestingly, this unexplored territory may explain the 
growing correlative evidence that patients with certain 
unrelated diseases, including Parkinson’s, for which 
bromocriptine is a therapy, have lower than expected rates 
of certain cancers [42].
Beyond its anti-proliferative and cytotoxic effects, 
bromocriptine demonstrates a preference for proliferative 
leukemic cells and appears to alter colony formation. 
These are key qualities in any hopeful treatment for bone 
marrow disease. All of these virtues, combined with its 
synergy with the gold-standard therapy make it a very 
exciting drug. It has the potential to improve the quality 
of life and longer-term outcome for those MDS and AML 
patients for whom high-intensity chemotherapy regimens 
are not an option.
MATERIALS AND METHODS
Gene expression datasets 
The gene expression dataset employed in this study 
was derived from two published datasets listed on the 
GEO repository as GSE13159 [10] and GSE15061 [11]. 
Both contain Affymetrix array data from mononuclear cell 
fraction transcriptomes. GSE13159 contains a mixture of 
both bone marrow and peripheral blood samples, whereas 
GSE15061 contains exclusively bone marrow. Only those 
profiles from normal or complex karyotype AML, MDS 
or healthy donor samples were included in this study. The 
OCI/AML-3 and MDS-L cell lines were also profiled in-
house on the Affymetrix platform using the same protocol 
and arrays as that published in the original MILE study 
mentioned above (GSE13159).
Prognostic classification stratification
The prognostic classifier (PC) algorithm previously 
published and described by Mills et al [11] was developed 
from a data set comprising samples from healthy donors, 
a range of MDS subtypes and AML. This classifier was 
robustly shown to be able to stratify patients into one 
of 3 groups (low, medium and high) based on their risk 
of transformation to AML. The MDS gene expression 
profiles from the combined datasets of 229 samples used 
in this study were stratified using this algorithm to classify 
each raw CEL file. This stratification was subsequently 
incorporated in further statistical analyses (as PC-Risk).
Identification of gene signature
The 229 original CEL files were downloaded and 
decompressed from the GEO online repository. The raw 
CEL files were imported into Partek Genomics Suite 
(PGS, version 6, St. Louis, Missouri 63005 U.S.A.). The 
data were normalized using RMA background correction 
with probe GC-content correction, quantile-normalization 
and median polish probe set summarization. During the 
import procedure the HGU133Plus2 Brainarray Chip 
Definition File (ENTREZG CDF version 16) was used to 
provide a more concise and accurate group of probe sets 
based on up-to-date probe sequence to NCBI Entrez Gene 
alignments [12]. The ANOVA algorithm in PGS was used 
to generate p-values for each ENTREZ-based probe set to 
identify significantly varying gene expression across the 
5 groups (normal, low/medium/high PC-Risk & AML). 
The following comparisons were also included as separate 
one-way ANOVAs to generate fold changes via least-
squares means of each group (LS-means). Any p-values 
generated were moderated using Benjamini-Hochberg 
false discovery rate (FDR) [43]. 
Normal vs Low PC-Risk MDS
Low PC-Risk MDS vs Medium PC-Risk MDS
Medium PC-Risk MDS vs High PC-Risk MDS
High PC-Risk MDS vs AML
sscMap identification of perturbagens
The sscMap algorithm depends on a reference 
set of gene expression profiles that represent various 
perturbagen-treated cells. The Broad Institute cmap02 
profiles were used in this study. They consist of 3730 
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individual reference profiles from a panel of ~1000 
compounds applied at various doses to the PC3, MCF7 
and HL-60 cell lines. The raw CEL files were downloaded 
and normalized using the Affymetrix-power-tools RMA-
sketch algorithm and the platform-appropriate Brainarray 
ENTREZG v16 CDF file, similarly to the study dataset. 
The reference data were from 3 separate platforms and 
therefore normalized in 3 batches. During the build of the 
“refset”, required by the sscMap tool, only those probe 
sets common to all platforms were included.
The previously identified gene signatures were 
formatted into tab-delimited tables of Probe IDs and 
positive or negative integers representing their ranks and 
up or down-regulation. These tables were then loaded 
into the sscMap tool. The algorithm was run, whereby it 
additionally generated 10, 000 random signatures of length 
corresponding to each signature and compared each with 
the Broad Institute “refset”. The tool then returned a list of 
positive or negative connection scores for each compound 
against each signature and a p-value based on the random 
permutation test. The p-value significance cut-off was 
based on an accepted false-positive rate of 1 per analysis, 
in other words 1/N where N = the number of comparisons, 
in this case 3730 reference profiles therefore ~0.00027. 
This p-value in the form −log10 (p-value) is equivalent to 
3.572.
Cell lines and primary material
All cell lines were maintained at 37°C and 5% CO2 
and cultured in RPMI1640+NaHCO3+L-Glut (Sigma-
Aldrich Company Ltd., Dorset, UK) supplemented 
with at least 10% FBS Superior (Biochrom AG) and 
1% Penicillin/Streptomycin. The OCI/AML-3 and 
OCI/AML-2 cell lines were sourced from DSMZ. The 
MDS-L cell line was a kind gift from Taoru Kohyama 
at the Kawasaki Medical School, Japan [44]. Its media 
was further supplemented with 1 mM UltraGlutamine I 
(Lonza Cologne GmbH, Köln, Germany), 10 mM HEPES 
(Cell Culture Grade, Sigma-Aldrich), 20 ng/mL hGM-
CSF (Cell Guidance Systems Ltd., Cambridge, UK) and 
10 IU/mL hIL-3 (CellGenix GmbH, Freiburg, Germany). 
The SKM-1 cell line was a kind gift from Stefan Fröhling 
(Nationales Centrum für Tumorerkrankungen, Heidelberg, 
Germany). Both the SKM-1 and MDS-L cell lines were 
validated using STR analysis as unique and pure (LGC 
Standards, Middlesex, UK). The SKM-1 STR markers 
matched those recorded in the DSMZ library. The MDS-L 
cell line, as it is not available from cell banks, was shown 
by karyotyping to have monosomy 7 and del (5q) as cited 
in the originating paper (Supplementary Figure 3) [44]. 
Ficolled bone marrow or peripheral blood samples 
from AML patients, obtained with consent, at diagnosis 
(Northern Ireland Ethical Approval: 08/NIR01/9) were 
diluted one in two with phosphate-buffered saline and 
then layered over one-third volume of Ficoll Paque Plus 
(GE Healthcare Life Sciences, Buckinghamshire, UK). 
After 30 minutes of centrifugation at 400 × g the buffy 
coat containing mononuclear cells was removed and 
washed twice with RPMI1640. Cells were then counted 
and cryogenically frozen in freezing medium (10% 
DMSO, 50% RPMI1640, 40% FBS). When required, cells 
were thawed at 37°C, washed once with RPMI-1640 and 
re-suspended in 10% FBS in RPMI1640 before treatment.
Screening compounds
Bromocriptine and Busprione were purchased 
from Tocris Bioscience (Bristol, UK) as mesylate and 
hydrochloride salts respectively. 
Other dopamine and serotonin agonists
All other screening compounds, except m-CPP 
(Sigma-Aldrich) were from Tocris Bioscience: Sumanirole 
(D2 agonist), Spiperone (5-HT2A serotonin and selective 
D2-like dopamine receptor antagonist), Lisuride (D2~4 
agonist), Pramipexole (D
2~4
 agonist), BW723C86 
(5-HT2B receptor agonist), m-CPP (Pan-serotonin agonist), 
Dihydrexidine (full agonist at the dopamine D1 and D5 
receptors), Cabergoline (D
2~4
 agonist, possible prolactin 
inhibitor), DL-TBOA (EAAT blocker)
Viability assay and synergy calculation
Cell viability post drug treatment was measured 
using the ViaLight™ ATP-based assay (Lonza), typically 
at 72 hours, unless otherwise stated. Relative Luminescent 
Units were normalized as a percentage of time-matched 
vehicle-treated control samples. Synergy was assessed by 
treating cells with the various combinations of 0.25, 0.5, 
1 and 2 × the 72H IC50 doses of both bromocriptine and 
cytarabine. The Combination Index values were calculated 
using the CalcuSyn software according to the method of 
Chou-Talalay et al [19, 45]. 
Western blotting
Cell lysates post-treatment were prepared using 
ProteoJET Cell Lysis Reagent (Fermentas, Vilnius, 
Lithuania) supplemented with Pierce Protease Inhibitor 
Cocktail (Thermo Scientific, Hemel Hempstead, UK) 
and 10 mM Sodium Fluoride and 20 mM Sodium 
Orthovanadate (Sigma-Aldrich). Lysates were then 
denatured at 70°C for 10 minutes in Bolt™ LDS-
based loading buffer supplemented with DTT (Life 
Technologies, Paisley, UK). The denatured samples were 
run on Bolt™ 12% Bis-Tris gels (Life Technologies) and 
transferred using standard Towbin Western transfer to 
0.2 μm Immobilon PVDF membranes (Millipore, Watford, 
UK). Antibodies were used at 1:1000: Cleaved Caspase 
3 (Cell Signaling Technology, Leiden, Netherlands), 
Oncotarget6617www.impactjournals.com/oncotarget
Caspase 3 (CST), PARP (C-2–10, Enzo Life Sciences, 
Exeter, UK) & β-actin (A5441, Sigma-Aldrich). 
Appropriate secondary antibodies (Dako, Ely, UK) were 
used at half the primary antibody concentration and 
developed using WesternBright ECL Reagent (Advansta, 
Menlo Park, USA).
Ex vivo methylcellulose
Cells were treated for 18 hours in liquid culture 
and counted. Subsequently 2 × 104 cells per mL were 
thoroughly mixed with pre-supplemented Methylcellulose 
media, without drug (HSC003, R & D Systems) and 
seeded into a 12-well plate at 250 µL per well. After 
9 days colonies were stained with 25 µL of 8 mg/mL 
Iodonitrotetrazolium (Sigma-Aldrich) solution in pure 
ethanol. After overnight staining, colonies were imaged 
and counted using the GelCount system (Oxford Optronix, 
Abingdon, UK) using consistent settings for all plates.
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